We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
According to results of the COLUMBA trial, which GSK says is the longest study of an anti-IL5 biologic treatment in severe eosinophilic asthma to be reported